

17 May 2018

Company Announcements Office
Australian Securities Exchange

Appendix 3Y Change of Director's Interest Notice

Attached is an Appendix 3Y – Change of Director's Interest Notice detailing a change in the relevant interests of Mr Maurie Stang, Non-Executive Chairman of Nanosonics Limited (**Nanosonics**).

The change in relevant interests involved the sale of 14,544 ordinary shares in Nanosonics held by Novapharm Research (Australia) Pty Ltd (**Novapharm**). Mr Stang does not hold a majority interest in Novapharm but is considered to have a relevant interest in the Nanosonics shares held by Novapharm because his voting power in Novapharm is above 20%.

Novapharm was a founding shareholder in Nanosonics and was the entity that originally filed certain core intellectual property that was subsequently assigned to a Nanosonics group company before Nanosonics listed on the ASX.

Following the sale of these securities, Mr Stang continues to hold 20,240,157 ordinary shares in Nanosonics, including 43,640 shares held by Novapharm.

Nanosonics Limited

A handwritten signature in dark ink, appearing to read "McGregor Grant", is positioned above the printed name and title.

McGregor Grant
Company Secretary

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Nanosonics Limited
ABN	11 095 076 896

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Maurie Stang
Date of last notice	12 March 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	a) Direct b) Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Indirect shares held in names of Novapharm Research (Australia) Pty Ltd, Epitek Corporation Pty Ltd and UBS Nominees Pty Ltd
Date of change	10 May 2018
No. of securities held prior to change	a) Direct: 14,000,302 ordinary shares, fully paid. b) Indirect: 6,254,399 ordinary shares, fully paid.
Class	Ordinary shares, fully paid.
Number acquired	Nil
Number disposed	14,544 ordinary shares.
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$37,526.33

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	a) Direct: 14,000,302 ordinary shares, fully paid. b) Indirect: 6,239,855 ordinary shares, fully paid (Note1).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On market sale of ordinary shares.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Director: Maurie Stang
Date: 17 May 2018

+ See chapter 19 for defined terms.